Welcome to our dedicated page for Evaxion AS news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion AS stock.
Evaxion A/S reports developments as a clinical-stage TechBio company using its proprietary AI-Immunology™ platform to design vaccine candidates for cancer and infectious diseases. Company news commonly covers EVX-01, its personalized peptide-based cancer vaccine for advanced solid cancers, including data from a phase 2 advanced melanoma trial and measures of neoantigen target selection and immune response.
Updates also address platform applications beyond melanoma, including glioblastoma vaccine design, prophylactic infectious disease concepts such as polio and cytomegalovirus programs, collaborations, business development activity, quarterly financial results, annual general meeting outcomes, board matters, and management-role changes.
Evaxion (NASDAQ: EVAX) will present new biomarker and immune data for its AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting.
The poster (Abstract #605, Poster #605) is titled "Immune correlates of clinical response following treatment with the personalized cancer vaccine EVX-01 and Pembrolizumab in advanced melanoma patients" and will be presented on November 7, 2025, 5:10–6:35 p.m. ET by Michail Angelos Pavlidis. Two-year efficacy data from the same phase 2 trial will be presented orally at ESMO 2025 on October 17, 2025. The phase 2 study evaluates EVX-01 plus KEYTRUDA (pembrolizumab) in advanced melanoma with individualized vaccines per patient.
Evaxion (NASDAQ: EVAX) has successfully out-licensed its vaccine candidate EVX-B3 to MSD (Merck) in a significant deal worth up to $592 million plus royalties. The agreement includes an immediate $7.5 million cash payment, extending Evaxion's cash runway to H1 2027.
MSD will take full responsibility for EVX-B3's development, which targets a pathogen associated with serious medical complications and currently has no available vaccines. The deal validates Evaxion's AI-Immunology™ platform technology.
Additionally, MSD has extended its evaluation period for a second vaccine candidate, EVX-B2 (targeting Gonorrhea), with a licensing decision expected in H1 2026. If exercised, this option would bring an additional $2.5 million upfront payment plus similar milestone payments and royalties.
Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has announced its participation in multiple scientific and investor conferences across the US, Europe, and Asia during H2 2025.
The company's Chief Scientific Officer and interim CEO Birgitte Rønø highlighted that their two-year clinical data for the personalized cancer vaccine EVX-01 has been selected for oral presentation at the ESMO congress in October. The conference schedule includes prestigious events such as the Vaccine Congress in Kyoto, HC Wainwright Global Investment Conference in New York, and the World Vaccine Congress Europe in Amsterdam.
Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company, reported Q2 2025 financial results and business updates. Key highlights include completion of EVX-01 phase 2 trial treatments, with full two-year clinical efficacy data to be presented at ESMO Congress in October 2025. The company received recognition through a Gates Foundation grant for polio vaccine development and expanded its pipeline with EVX-B4 for Group A Streptococcus.
Financial position improved with $14.7 million in cash as of June 30, 2025, sufficient until mid-2026. The company converted €3.5 million of EIB debt to equity at a 89% premium. Q2 2025 resulted in a net loss of $4.8 million ($0.02 per share), compared to $6.2 million loss in Q2 2024. R&D expenses decreased to $2.2 million from $2.8 million year-over-year.
Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has scheduled its Q2 2025 financial results and business update for August 14, 2025, before Nasdaq CM market opening.
The company will host a conference call and webcast at 14:30 CET/08:30 EST on the same day, where Executive Management will present the results and take questions. Participants must pre-register to receive dial-in details and a PIN code. The webcast recording will be available on Evaxion's website after the event.
Evaxion (NASDAQ: EVAX) announced it will present two-year clinical efficacy data from its phase 2 trial of EVX-01, an AI-designed personalized cancer vaccine for advanced melanoma, at the ESMO Congress 2025 in Berlin. The trial combines EVX-01 with MSD's KEYTRUDA® and has shown promising results, with interim one-year data demonstrating a 69% Overall Response Rate and tumor reduction in 15 out of 16 patients.
The presentation will take place on October 17, 2025, featuring data that validates their AI-Immunology™ platform's predictions, which showed significant correlation (p=0.00013) with immune responses to the personalized vaccine's neoantigens. Each patient in the trial received a unique vaccine designed based on their individual biology.
Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has finalized a significant debt-to-equity conversion agreement with the European Investment Bank (EIB). Under the agreement, EIB will convert €3.5 million of its existing €7 million loan into equity through warrant purchases at $4.87 per share, representing an 89% premium to the previous day's closing price.
The strategic transaction immediately strengthens Evaxion's equity position by $4.1 million (€3.5 million), while significantly reducing the company's debt burden. This restructuring is expected to enhance Evaxion's financial flexibility and improve cash flow, marking a positive development in the company's financial management strategy.
Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has announced significant changes to its executive management team. CEO Christian Kanstrup has stepped down, with Chief Scientific Officer Dr. Birgitte Rønø appointed as interim CEO while the company searches for a permanent replacement.
The company has also appointed Thomas Schmidt as permanent Chief Financial Officer, following his interim role since November 2024. These management changes are part of Evaxion's strategy to optimize value from its proprietary AI-Immunology™ platform and pipeline developed over 17 years.
The Board of Directors is conducting a search for a new permanent CEO with strong business development focus, proven transformational leadership, and strategic partnership capabilities. Dr. Rønø, who has been with Evaxion since 2017 and joined Executive Management in 2021, will ensure leadership continuity during the transition period.
Evaxion (NASDAQ: EVAX) has announced the addition of a new vaccine program, EVX-B4, targeting Group A Streptococcus (GAS) to its R&D pipeline. Initial computational analysis shows that the company's AI-Immunology™ platform can successfully identify novel vaccine targets to combat GAS, which affects hundreds of millions globally each year.
The bacteria can cause severe complications including rheumatic heart disease, necrotizing fasciitis, strep throat, and scarlet fever. The development of EVX-B4 represents a significant milestone in Evaxion's 2025 objectives, bringing their pipeline to eight vaccine candidates - five for infectious diseases and three for cancer.